ChemicalBook > CAS DataBase List > MGA271

MGA271

Product Name
MGA271
CAS No.
1353485-38-7
Chemical Name
MGA271
Synonyms
MGA271;Enoblituzumab;MGA271|||TJ-271;Enoblituzumab (anti-CD276);Research Grade Enoblituzumab;Research Grade Enoblituzumab(DHJ04001)
CBNumber
CB13303237
Formula Weight
0
MOL File
Mol file
More
Less

MGA271 Property

form 
Liquid
color 
Colorless to light yellow
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

MGA271 Chemical Properties,Usage,Production

Uses

Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators[1].

in vivo

Enoblituzumab (5 mg/kg; i.v.; single dose) exhibits estimated half-life of 249 hours with a Cmax of 43 mg/mL in mice (mCD16-/-hCD16A+) that murine CD16 gene knocked out and are transgenic for human CD16A-158F[3].
Enoblituzumab (0.1-10 mg/kg; i.v.; once weekly; 5 weeks) exhibits potent antitumor activity in B7-H3-expressing xenograft mice models of renal cell and bladder carcinoma[3].

Animal Model:mCD16-/-hCD16A+ mice implanted with A498 renal cell carcinoma, 786-0 renal cell carcinoma, or HT-1197 bladder carcinoma cells (s.c.)[3]
Dosage:1 mg/kg, 5 mg/kg, 10 mg/kg
Administration:Intravenous injection; once weekly; 5 weeks
Result:Significantly inhibited tumor growth at doses of 1 mg/kg or greater with once weekly treatment.
Achieved a cytostatic response at 5 or 10 mg/kg until day 52, after which the average tumor volume of the 5 mg/kg treatment group remained near predose administration levels, whereas a nonsignificant trend toward relapse exhibited in the 10 mg/kg group.

References

[1] Hińcza-Nowak K, et al. Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy. Genes (Basel). 2021 Sep 28;12(10):1534. DOI:10.3390/genes12101534
[2] Chapoval, et al. Immune Checkpoints of the B7 Family. Part 2. Representatives of the B7 Family B7-H3, B7-H4, B7-H5, B7-H6, B7-H7, and ILDR2 and Their Receptors. Russ J Bioorg Chem 45, 321–334 (2019).
[3] Loo D, et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res. 2012 Jul 15;18(14):3834-45. DOI:10.1158/1078-0432.CCR-12-0715

MGA271 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

MGA271 Suppliers

TargetMol Chemicals Inc.
Tel
+1-781-999-5354; +17819995354
Email
marketing@targetmol.com
Country
United States
ProdList
32435
Advantage
58
Aladdin Scientific
Tel
Email
tp@aladdinsci.com
Country
United States
ProdList
57505
Advantage
58

1353485-38-7, MGA271Related Search:


  • MGA271
  • Enoblituzumab
  • Research Grade Enoblituzumab(DHJ04001)
  • Enoblituzumab (anti-CD276)
  • MGA271|||TJ-271
  • Research Grade Enoblituzumab
  • 1353485-38-7